PEER-REVIEW REPORT

Name of journal: World Journal of Stem Cells

Manuscript NO: 57521

Title: Perspectives on mesenchymal stem/progenitor cells and their derivates as potential therapy in lung damage caused by COVID-19

Reviewer's code: 03448879

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Professor, Surgeon

Reviewer's Country/Territory: China

Author's Country/Territory: Poland

Manuscript submission date: 2020-06-12

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-06-12 13:04

Reviewer performed review: 2020-06-18 15:03

Review time: 6 Days and 1 Hour

Scientific quality	[Y] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [Y] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The article thoroughly reviewed the cell-based therapy with MSCs and/or their secretome as a supportive therapy for critically ill COVID-19 patients, providing insights into the treatment modalities of this yet unconquered disease. Minor grammatical errors and typos need to be corrected. In general, this article is interesting and well written.

Scientific quality	[Y] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

There are still language errors in "Current therapies of COVID-19" in Introduction. To be specific, "previouslyâ€'recognized", "AEC2", "criticallyâ€'ill", "treatment critically-ill COVID-19 patients". The rest of the manuscript is accurate.